PRIMARY STUDY

Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Key Findings:  Urinary levels of liver-type fatty acid binding protein (L-FABP) appear to accurately correlate with the severity of kidney disease in patients with diabetic kidney failure.